成为国内首个且唯一*获批用于3岁及3岁以上该患者人群的治疗药物 上海2026年3月30日 /美通社/ -- 阿斯利康宣布,中国国家药品监督管理局已正式批准科赛优®(硫酸氢司美替尼胶囊),一种选择性、口服MEK抑制剂,用于3岁及3岁以上伴有症状、无法手术的丛状神经纤维瘤(PN)的1型神经纤维瘤病(NF1)儿童及成人患者的治疗[1]。 此次获批是基于Ⅲ期临床试验KOMET的阳性结果,该研究是NF1-...
Source Link成为国内首个且唯一*获批用于3岁及3岁以上该患者人群的治疗药物 上海2026年3月30日 /美通社/ -- 阿斯利康宣布,中国国家药品监督管理局已正式批准科赛优®(硫酸氢司美替尼胶囊),一种选择性、口服MEK抑制剂,用于3岁及3岁以上伴有症状、无法手术的丛状神经纤维瘤(PN)的1型神经纤维瘤病(NF1)儿童及成人患者的治疗[1]。 此次获批是基于Ⅲ期临床试验KOMET的阳性结果,该研究是NF1-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.